Healthcare provider profile · identity verified

Christopher S Luthi, MD

Internal Medicine · MILFORD, CT · NPI 1518100072

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Trazodone Hcl	Trazodone Hcl	318	43
Amlodipine Besylate	Amlodipine Besylate	253	40
Atorvastatin Calcium	Atorvastatin Calcium	251	36
Eliquis	Apixaban	237	28
Quetiapine Fumarate	Quetiapine Fumarate	218	22
Levothyroxine Sodium	Levothyroxine Sodium	184	30
Gabapentin	Gabapentin	179	21
Sertraline Hcl	Sertraline Hcl	148	20
Mirtazapine	Mirtazapine	140	24
Pantoprazole Sodium	Pantoprazole Sodium	139	26
Lisinopril	Lisinopril	135	19
Metformin Hcl	Metformin Hcl	135	15
Januvia	Sitagliptin Phosphate	134	suppressed
Potassium Chloride	Potassium Chloride	129	suppressed
Furosemide	Furosemide	128	22
Rosuvastatin Calcium	Rosuvastatin Calcium	112	22
Metoprolol Succinate	Metoprolol Succinate	109	17
Famotidine	Famotidine	99	15
Risperidone	Risperidone	94	suppressed
Duloxetine Hcl	Duloxetine Hcl	89	suppressed
Losartan Potassium	Losartan Potassium	89	15
Donepezil Hcl	Donepezil Hcl	88	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	79	13
Tamsulosin Hcl	Tamsulosin Hcl	77	14
Escitalopram Oxalate	Escitalopram Oxalate	76	14
Carvedilol	Carvedilol	66	11
Clopidogrel	Clopidogrel Bisulfate	66	12
Pravastatin Sodium	Pravastatin Sodium	64	suppressed
Bupropion Xl	Bupropion Hcl	62	suppressed
Levetiracetam	Levetiracetam	59	suppressed
Jardiance	Empagliflozin	56	suppressed
Diclofenac Sodium	Diclofenac Sodium	54	15
Myrbetriq	Mirabegron	54	suppressed
Xarelto	Rivaroxaban	51	suppressed
Entresto	Sacubitril/Valsartan	50	suppressed
Benztropine Mesylate	Benztropine Mesylate	47	suppressed
Montelukast Sodium	Montelukast Sodium	47	suppressed
Finasteride	Finasteride	46	suppressed
Allopurinol	Allopurinol	44	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	42	suppressed
Spironolactone	Spironolactone	42	suppressed
Aripiprazole	Aripiprazole	40	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	39	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Clozapine	Clozapine	38	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	37	suppressed
Torsemide	Torsemide	37	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	suppressed
Heparin Sodium	Heparin Sodium,porcine	35	suppressed
Hydralazine Hcl	Hydralazine Hcl	35	suppressed
Divalproex Sodium	Divalproex Sodium	34	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Tradjenta	Linagliptin	33	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	30	suppressed
Omeprazole	Omeprazole	30	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	29	suppressed
Memantine Hcl	Memantine Hcl	29	suppressed
Colchicine	Colchicine	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	28	suppressed
Lactulose	Lactulose	28	11
Methocarbamol	Methocarbamol	28	suppressed
Cholestyramine	Cholestyramine (With Sugar)	27	suppressed
Memantine Hcl Er	Memantine Hcl	27	suppressed
Naproxen	Naproxen	27	suppressed
Anastrozole	Anastrozole	26	suppressed
Otezla	Apremilast	25	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	25	suppressed
Sucralfate	Sucralfate	25	suppressed
Calcium Acetate	Calcium Acetate	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Mupirocin	Mupirocin	22	suppressed
Atenolol	Atenolol	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	20	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	20	suppressed
Haloperidol	Haloperidol	20	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	20	14
Vancomycin Hcl	Vancomycin Hcl	20	suppressed
Baclofen	Baclofen	19	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Divalproex Sodium Er	Divalproex Sodium	19	suppressed
Humalog	Insulin Lispro	19	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Prednisone	Prednisone	19	suppressed
Olanzapine	Olanzapine	18	suppressed
Cefepime Hcl	Cefepime Hcl	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	11
Simvastatin	Simvastatin	17	suppressed
Tresiba Flextouch U-100	Insulin Degludec	17	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Dalfampridine Er	Dalfampridine	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Micafungin	Micafungin Sodium	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Kapspargo Sprinkle	Metoprolol Succinate	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Dapagliflozin	Dapagliflozin Propanediol	12	suppressed
Ertapenem	Ertapenem Sodium	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Minoxidil	Minoxidil	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Levemir Flexpen	Insulin Detemir	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Sodium Chloride	0.9 % Sodium Chloride	11	suppressed
Tivicay	Dolutegravir Sodium	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error